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Abstract: Socially responsible technologies are designed while taking into consideration the
socioeconomic, geopolitical and environmental limitations of regions in which they will be
implemented. In the medical context, this involves making therapeutic platforms more accessible
and affordable to patients in poor regions of the world wherein a given disease is endemic.
This often necessitates going against the reigning trend of making therapeutic nanoparticles ever
more structurally complex and expensive. However, studies aimed at simplifying materials and
formulations while maintaining the functionality and therapeutic response of their more complex
counterparts seldom provoke a significant interest in the scientific community. In this review we
demonstrate that such compositional simplifications are meaningful when it comes to the design
of a solution for osteomyelitis, a disease that is in its natural, non-postoperative form particularly
prevalent in the underdeveloped parts of the world wherein poverty, poor sanitary conditions, and
chronically compromised defense lines of the immune system are the norm. We show that calcium
phosphate nanoparticles, which are inexpensive to make, could be chemically designed to possess
the same functionality as a hypothetic mixture additionally composed of: (a) a bone growth factor;
(b) an antibiotic for prophylactic or anti-infective purposes; (c) a bisphosphonate as an antiresorptive
compound; (d) a viral vector to enable the intracellular delivery of therapeutics; (e) a luminescent dye;
(f) a radiographic component; (g) an imaging contrast agent; (h) a magnetic domain; and (i) polymers
as viscous components enabling the injectability of the material and acting as carriers for the sustained
release of a drug. In particular, calcium phosphates could: (a) produce tunable drug release profiles;
(b) take the form of viscous and injectable, self-setting pastes; (c) be naturally osteo-inductive and
inhibitory for osteoclastogenesis; (d) intracellularly deliver bioactive compounds; (e) accommodate
an array of functional ions; (f) be processed into macroporous constructs for tissue engineering; and
(g) be naturally antimicrobial. All in all, we see in calcium phosphates the presence of a protean
nature whose therapeutic potentials have been barely tapped into.
Keywords: antimicrobials; biomaterials; biomedicine; calcium phosphate; drug delivery;
hydroxyapatite; nanomaterials; nanotechnology; social responsibility; sustainability
1. Introduction
“I have to leave the convent and consecrate myself to the poor” [1].
Mother Teresa, Calcutta—Darjeeling train, 1946.
Socially responsible design of nanomaterials, including therapeutic nanostructures, is rarely
addressed. Only one publication listed in Elsevier’s bibliographic database Scopus contains both the
terms “socially responsible” and “nano” [2]. Socially responsible design is tied to the aim of acting for
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the benefit of society at large and oftentimes involves making the product affordable to impoverished
populations through structural and compositional simplification. This approach, however, clashes
with the common assumption that the more structurally and functionally complex the nanoparticle,
the greater its applicative potentials. For this reason, structural and functional complexification of
nanoparticles elicits a greater interest from the scientific community than their simplification. Quite
often, however, an extensive cost is associated with synthesis and characterization (necessary to verify
the structure and the correct composition) of such complex nanostructures. As such, their consideration
for a prompt therapeutic application in poor regions of the world and underprivileged communities is
equivocal, if not illusory.
One example comes from osteomyelitis, the disease that is prevalent in poor sanitary conditions
typical for underdeveloped regions of the world [3]. Although an interest for finding more advanced
and patient-friendly solutions to it has recently emerged because the disease is often secondary to bone
surgeries [4,5], the frequency of which follows in step with the continuously aging average population
of the developed world, in its natural form it is predominantly present in environments where low
hygiene, malnutrition, other infectious diseases, compromised immunity and poverty are endemic.
Figure 1a, for example, illustrates the disparity between the percentage of hospitalizations due to bone
infection in the US and in Africa: 1%–2% vs. 7%–20%, respectively. In this non-postoperative form,
the disease is, moreover, particularly known for striking children [6]. Ideally, therefore, the therapy
for osteomyelitis should be affordable to the inhabitants of poorer regions of the world than those in
which the most advanced tissue engineering solutions for bone disease are being developed today.
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debridement of the infected and necrotic tissue [11,12]. This rather invasive therapy suffers from 
Figure 1. (a) Percentage of hospitalizations due to osteomyelitis, equaling 1.23% in the United States
and ranging from 7% to 20% in Africa. The area elow and above 7% differs in color—yellow and
red, respectively. Data retrieved from Refs. [7–9]; (b) Percentage of mineral, organic, and aqueous
components of three major hard tissues in the human body, demonstrating calciu phosphate (CAP)
as the most abundant component of each of the three of them: bone, dentin and enamel. Adapted
from [10] with permission from ©2008 Mineralogical Society of America.
Typical therapies for osteomyelitis include oral or parenteral administrations of antibiotics ranging
in duration from 2–6 weeks depending on the severity of infection as well as surgical debridement
of the infected and necrotic tissue [11,12]. This rather invasive therapy suffers from numerous
drawbacks, including (a) the side effects tied with systemic distribution of antibiotics; (b) their
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low bioavailability due to impaired vascularization of an already lowly vascularized boney tissues;
(c) skeletal disfigurement resulting from the surgical intervention; and (d) the risk of new infection
accompanying open surgery [13]. Therefore, attempted to be developed are therapies involving the
minimally invasive injection of a colloidal carrier with (a) sustained antibiotic release profiles for local
delivery; and (b) osteogenic properties so as to minimize bone loss and maximize its regeneration. The
pivotal place in many of them is occupied by calcium phosphate (CAP), the major component of all
hard tissues in the human body (Figure 1b).
CAP is a material capable of exhibiting an unusually wide variety of properties; it is this versatility
of CAP that presents the basis for its consideration as a candidate for the key material for socially
responsible tissue engineering. As an illustration of this point, Figure 2 depicts two hypothetic
formulations. One of them contains (a) CAP as a central ingredient, i.e., the filler, so to speak; (b) a bone
growth factor, e.g., bone morphogenetic protein-2; (c) an antibiotic for prophylactic or anti-infective
purposes; (d) a bisphosphonate as an antiresorptive compound; (e) a viral vector to enable the
intracellular delivery of therapeutics; (f) a luminescent dye; (g) a radiographic component; (h) an
imaging contrast agent; (i) a magnetic domain; (j) one polymer as a viscous component enabling the
injectability of the material; and (k) another one acting to allow for the sustained release of a drug.
The other one contains only CAP. If we were to ask the patients, the clinicians, the chemists, and the
regulatory agencies which of these formulations would be preferred, there is no doubt that everybody
would be in favor of the latter. The reasons are obvious: the compositional and synthetic simplicity,
lower fabrication costs, greater availability of the reagents, higher technological transferability, in situ
synthesizability and a lesser risk of side effects. Table 1, for example, illustrates how economical
CAPs, at the price of 6–12 cents per gram, are compared to all the other commercially available
components of advanced bone graft formulations, some of which exceed the cost of CAPs by ten orders
of magnitude (e.g., the angiogenic growth factor TGF-β whose current price exceeds $200 million
per gram). However, how could CAP alone possess all these properties imparted to a bone graft
material by the aforementioned additives? In what follows we will try to convince the reader that the
formulations are indeed possible wherein CAP per se would possess all the sundry of properties that
an ideal bone graft material should possess. We will uncover some of the properties and functionalities
displayable by CAP that prove the protean nature of this solid whose peculiarity is analogous to that
of water in the realm of liquids [14]. Clinicians who have derogatorily compared the implantation of
CAP to the implantation of “stones” [15] might be pleasantly surprised upon the realization of this
myriad of exciting properties latently concealed in the structure of the seemingly unattractive and
simple material that CAP is. The elucidation of this versatility of properties was presented in earlier
review studies [16]; here it serves the sole role of supporting the reasons for which CAP could be seen
as fundamental to the new generation of socially responsible materials for tissue engineering and other
biomedical applications.
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properties of the multicomponent formulation. Given their identical medical performance, the social
responsibility levels of the two would differ: the first ones would be classified as low and the second
ones as high.
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Table 1. The prices for commercially available chemical components of advanced bone graft
formulations, listed together with companies producing them. By far the cheapest of them calcium
phosphates (CAPs), are colored in red. Prices are given for raw compounds and do not include the cost
of processing into forms tailored for specific medical applications, e.g., microspheres, macroporous
constructs, etc.
Class of Chemical Chemical Company Price per Gram
Antibiotic
Gentamycin Thermo Fisher $110
Vancomycin Sigma Aldrich $51.50
Ciprofloxacin Alfa Aesar $11.10
Growth factor
IGF-1 Sigma Aldrich $4,540,000
TGF-β 1 Alfa Aesar $204,000,000
BMP-2 Thermo Fisher $12,000,000
BMP-4 Thermo Fisher $19,000,000
BMP-7 Thermo Fisher $19,000,000
Bisphosphonate
Alendronic acid Sigma Aldrich $1,690
Zoledronic acid Sigma Aldrich $466.70
Pamidronic acid Sigma Aldrich $4812
Mineral compound Calcium phosphate Sigma Aldrich $0.12
Calcium phosphate Alfa Aesar $0.06
Drug release polymer
PLGA Sigma Aldrich $67.40
PEO Alfa Aesar $0.71
PLLA Sigma Aldrich $45.00
Viscous polymer
Polyurethane injectables Sigma Aldrich $23.50
PCL Sigma Aldrich $8.74
Chitosan Alfa Aesar $0.84
Hyaluronic acid Sigma Aldrich $26,700
Luminescent dye
Oxytetracycline Sigma Aldrich $1,632
Calcein green Thermo Fisher $313,000
Alizarin red Sigma Aldrich $2.40
Xylenol orange Sigma Aldrich $41.00
2. CAP as a Tunable Drug Release Carrier and a Viscous, Self-Setting Material for Injectable
Bone Grafts
CAP has plenty of properties for which it is desired in bone graft formulations [17]. It is a bioactive,
biocompatible, biodegradable, osteoconductive, non-immunogenic component of bone. If we were to
take into account the ancient Latin maxim, similia similibus curantur (“like cures like”), it could indeed
be considered as an ideal component of tissue engineering constructs for the replacement of bone.
However, being a ceramic material, CAP is all but an ideal drug delivery carrier. Namely, the lattice
formation energy is large enough to expel most organic molecules precipitated together with CAP.
Therefore, unlike polymers, which could entrap drugs inside the particle, no organic molecule larger
than glycine can be accommodated inside the crystal lattice of CAP through intercalation (even the
entrapment of glycine inside hydroxyapatite is conditioned by defects in the lattice and the presence of
paired OH´ and Ca2+ vacancies) [18]. On top of this, the presence of the hydrated and intensely mobile
layer of ions, whose crystalline order, if any, has little in common with the bulk of the particle [19,20],
allows for the rapid exchange of ions across the particle/solution interface and disables stable chemical
bonding of organic molecules to the CAP particle surface. This inherently unstructured and mobile
surface layer of CAP particles in solution, unlike that typifying most oxide ceramics, also allows for the
characteristic, aggregational growth of CAP particles [21], whereby smaller, amorphous or crystalline
units get “sintered” under ambient conditions thanks to the low energy barrier for the coalescence of
their diffusive, highly hydrated surfaces. Such aggregational growth, in theory, makes the entrapment
of organics within ultrafine CAP nanoparticle aggregates possible, though this is still a terra incognita
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in our understanding of CAP/organic interface. Nevertheless, drug loading via co-precipitation onto
CAP at the atomic scale is limited to physisorption, given that there is no ability to entrap the drug
within the crystal lattice or have it chemically conjugated to the surface. On one hand, owing to
the alternation of intensely charged multivalent species (Ca2+, PO43´) on the particle surface, CAP
can relatively strongly bind a variety of organic molecules [22–24]. On the other hand, such strong
binding usually does not stand in the way of a considerable amount of burst release that occurs in
the first minutes of the contact of the material with the solution [25]. To promote sustained release of
drugs from CAPs, such as that achievable using biodegradable polymers [26–28], thus stands as an
enormous challenge.
Figure 3, however, demonstrates that sustained drug release from pure CAP nanopowders and
colloidal pastes is possible. Figure 3a shows four distinct profiles for the release of serum albumin
from four CAP nanopowders with different monophasic compositions and different corresponding
solubility values [29]. The latter range from 17 g/dm3 for monocalcium phosphate monohydrate
(MCPM) to 48 mg/dm3 for dicalcium phosphate anhydrous, a.k.a. monetite (DCPA) to 0.8 mg/dm3 for
amorphous calcium phosphate (ACP) to 0.3 mg/dm3 for hydroxyapatite (HAP) [30], demonstrating
that solubility can be made directly proportional to drug release rates if the phase composition of CAP
particles as the carrier is being precisely controlled. The release in this case is, however, driven by
undersaturation, not diffusion of the drug outside of the carrier. It is also conditioned by the loading of
the drug inside the pores formed by the desiccation-caused compaction of the nanoparticles into a solid
form. This implies that the application of such a biomaterial as a bone graft is limited to implantation.
Such a release control can also be called tailorable, in a sense that different phase compositions yield
different release profiles. However, because no setting of the release properties to any given value
within a finite range is possible using one such approach, this form of release control cannot be called
tunable as well. Tunability, in the real sense of the word, implies a process of control analogous to the
tuning of a radio frequency along a continuous range of frequencies until a desired station playing at a
precise frequency is located. To that end, a relationship must be established between the drug release
rate and the value of a structural parameter variable within a continuous range. Now, that a truly
tunable release from colloidal CAP pastes is possible is shown in Figure 3b. In this case, a complete
control over release properties within the range between 0 hours and 14 days is achieved by control
over the weight ratio between two differently prepared CAP components in the final mixture [31]. Both
components are hydroxyapatite in phase and what they differ in is merely the kinetics of the phase
transformation from the as-precipitated amorphous phase to the crystalline final product. Unlike in
the case shown in Figure 3a, the release of the antibiotic is driven by diffusion, not dissolution of the
carrier, as no considerable degradation of CAP is observed to entail the drug release. Also, in contrast
to thoroughly solid CAP from Figure 3a, CAP from Figure 3b is a moldable and cohesive self-setting
paste capable of accommodating to the geometry of the bone cavity and solidifying with a similarly
tunable kinetics as that typifying the drug release. To that end, it is shown that CAP, albeit a ceramic
material, could be made viscous so as to enable the minimally invasive injection into the bone defect
site and its thorough filling, without compromising the sustained release of drugs from the material.
Most importantly, this means that polymers as viscous components of CAP bone grafts [32–34] and
components allowing for sustained drug release profiles to be attained might soon be disposed of
as excessive.
The two examples shown in Figure 3 demonstrate the versatility of sustained drug release
mechanisms achievable using CAP particles as carriers. They also hint at the superfluity of polymers
as sustained drug release components of materials for bone regeneration. Eliminating the need for
such polymers comes along with multiple benefits, including (a) the reduced cost of preparation;
(b) increased scalability; and (c) the solution for the inevitable presence of remnant organic solvent
molecules in formulations containing polymers. Namely, in contrast to polymers and lipids, which are
precipitated from organic solvents, all CAP nanoparticles reported in this review have been crystallized
Materials 2016, 9, 434 6 of 27
from aqueous solutions. This gives them an immediate advantage over polymers from the clinical
safety perspective [35].
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Figure 3. (a) Release of serum albumin (FITC-BSA) over time from different monophasic CAP
nanopowders: hydr xyapatite (HAP), amorphous CA (ACP), dicalcium phosphate anhydrous
(DCPA), nd monoca cium phosphate monohydrate (MCPM); (b) Release of vancomycin from CAP
pastes is controllable by the weight ratio between two different hydroxyapatite components, HAP1
and HAP2, and tunable to anywhere between 0 h and 2 weeks.
3. CAP as an Intracellular Delivery Carrier
CAP n nopar icles all w fo an effi ie intracellular delivery of geneti material and other
biomolecules [36,37]. For this reason, CAP has been considered a major non-viral transfection agent
and a safer alternative to its viral vector counterparts [38]. The mechanism of transfection using CAP
nanoparticles, schematized in Figure 4a, is as follows: CAP particles loaded with oligonucleotides
are endocytosed via caveolae- or clathrin-mediated pathways [39,40] in a matter of hours following
their ad ti n to the medium sur ounding the cells [41] (Figure 4b). Travelling down the endosomal
route from the membrane toward the nucleus, the endosome encapsulating CAP particles transition
into acidic lysosomes threatening to degrade the nucleic acid cargo. However, CAP begins to partially
dissolve already at the comparatively low pH typifying the late endosome, enabling the escape of the
nucleic acids before they become cleaved by lysosomal nucleases. This partial dissolution of CAP not
only liberates the adsorbed nucleic acids, but also destabilizes the lysosomal membrane by releasing
Ca2+ ions and blocking the proton pumps thanks to the release of hydroxyl groups. The path of the
released n cleic acid from there on depends on its nature: whereas plas id DNA must make it to
the cell nucleus in order to be transcribed, siRNA need not leave the cytoplasm for gene silencing
using the means to be achieved [42]. Ideally, plasmid DNA thus travels on its own to the nucleus
where it becomes transcribed to mRNA, which subsequently becomes translated to a particular protein
structure (Figure 4d). Depending on whether the delivered DNA strand becomes transcribed outside
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of the genome or becomes incorporated to it, the transfection would be either transient, fading after a
few cell division cycles, or permanent. Although CAP nanoparticles can enter the nucleus [43], they are
mainly limited to the extranuclear region of the cell. Bioresorbable as they are, CAP particles become
degraded down to constitutive ions, which are then included in the metabolic cycles of the tissue or the
organism in question. No negative effects on kidneys or other organs are usually observed as a result
of the bioresorption of CAP, suggesting that the risks of ectopic calcification following this resorption
process and the elevation of calcium and phosphate concentrations in the serum are minimal [44].
Materials 2016, 9, 434 7 of 26 
 
are mainly limited to the extr nuclear region of the cell. Bioresorbable as they are, CAP particles 
become degraded down to constitutive ions, which are then included in the metabolic cycles of the 
tissue or the organism in question. No negative effects on kidneys or other organs are usually 
observed as a result of the bioresorption of CAP, suggesting that the risks of ectopic calcification 
following this resorption process and the elevation of calcium and phosphate concentrations in the 
serum are minimal [44]. 
 
Figure 4. (a) Mechanism of the uptake of CAP nanoparticles carrying a nucleic acid (plasmid DNA) 
into the cell: (I) contact with the cell membrane; (II) uptake via endocytosis; (III,IV) endosomal escape 
and release into the cytoplasm; (V) a journey toward the nucleus; (VI) nuclear entry and gene 
expression. Obtained from [45] with permission from ©2008 John Wiley & Sons; (b) A confocal optical 
micrograph showing the uptake of conglomerates of CAP nanoparticles (green) delivering 
clindamycin inside MC3T3-E1 cells (blue = nucleus, red = f-actin); (c) The intensity of fluorescence of 
intracellular colonies of S. aureus co-cultured with osteoblastic MC3T3-E1 cells (C+) statistically 
insignificantly decreasing following the treatment with pure clindamycin (CL), but significantly 
decreasing following the treatment with clindamycin-loaded hydroxyapatite (HAP/CL) and 
amorphous calcium phosphate nanoparticles (ACP/CL). Bars represent averages and values 
statistically significant (p < 0.05) compared to the positive control (C+) are marked with *; (d) A 
confocal optical micrograph showing the transfection of a single MC3T3-E1 cell with a fluorescent 
protein (purple) in cases when CAP nanoparticles (green) carry a plasmid DNA cargo encoding for 
the given protein; (e) eGFP fluorescence intensity as a measure of the transfection rate in osteoblastic 
MC3T3-E1 cells transfected using CAP nanoparticles or PolyPlus jetPRIME as the carrier for an 
identical amount of pDNA encoding for eGFP. 
Figure 4. (a) Mechanism of the uptake of CAP nanoparticles carrying a nucleic acid (plasmid DNA)
into the cell: (I) contact with the cell membrane; (II) uptake via endocytosis; (III,IV) endosomal
escape and release into the cytoplasm; (V) a journey toward the nucleus; (VI) nuclear entry and gene
expression. Obtained from [45] with permission from ©2008 John Wiley & Sons; (b) A confocal optical
micrograph showing the uptake of conglomerates of CAP nanoparticles (green) delivering clindamycin
inside MC3T3-E1 cells (blue = nucleus, red = f-actin); (c) The intensity of fluorescence of intracellular
colonies o S. aureus co-cultured with osteoblastic MC3T3-E1 cells (C+) statistically insig ificantly
decreasing following the treatm nt with pure cli i (CL), but significantly decreasing following
the treatment with clindamycin-loaded hydroxyapatite (HAP/CL) and amorphous calcium phosphate
nanoparticles (ACP/CL). Bars represent averages and values statistically significant (p < 0.05) compared
to the positive control (C+) are marked with *; (d) A confocal optical micrograph showing the
transfection of a single MC3T3-E1 cell with a fluorescent protein (purple) in cases when CAP
nanoparticles (green) carry a plasmid DNA cargo encoding for the given protein; (e) eGFP fluorescence
intensity as a measure of the transfection rate in osteoblastic MC3T3-E1 cells transfected using CAP
nanoparticles or PolyPlus jetPRIME as the carrier for an identical amount of pDNA encoding for eGFP.
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CAP nanoparticles could be optimized by controlling the chemical conditions of their
co-precipitation with oligonucleotides to surpass commercially available non-viral carriers in terms of
transfection efficiency [46]. This is demonstrated in Figure 4e, where the enhanced green fluorescent
protein (eGFP) transfection rate achieved using CAP carriers is shown to markedly exceed that
promoted by a commercial carrier, Polyplus JetPRIME. Another effect in which CAP outperforms
its competitor is the extended period over which the transfection process occurs, all presumably
thanks to the slower degradation of CAP nanoparticles inside the cell compared to softer non-viral
carriers, such as lipoprotein complexes, phospholipid vesicles or cationic surfactants. Through the
control of supersaturation ratio, the precursor solutions mixing rate, pH, ionic strength, concentration
of additives, and other synthesis parameters, the size of the particles and, most importantly, their
exact agglomeration degree (moderate agglomeration is thought to protect pDNA and facilitate
transport across the cell membrane) could be optimized to yield relatively high transfection rates.
Further progress in this optimization process might be inextricably tied to the more fundamental
understanding of the interaction between oligonucleotides and CAP nanoparticles. The structure of
complexes between CAP nanoparticles and nucleic acids (pDNA, siRNA, etc.) is, however, still far from
being elucidated. One view holds that nucleic acids serve as nucleation surfaces around which CAP
nanoparticles crystallize, forming virtual agglomerates held together by the centrally located nucleic
acid molecules [47,48]. The alternative view holds that the entrapment of oligonucleotides within the
loose agglomerates of CAP nanoparticles is not possible and their physisorption on the particle surface
is the only possible scenario. With the further progress in transmission electron microscopy techniques
and particularly the ability to focus onto the interface between soft and hard matter, perhaps the fine
structure of these complexes will be revealed.
Another type of molecule in need of efficient intracellular delivery using nanoparticles is
an antibiotic [49]. Namely, chronic, recurrent osteomyelitis is accompanied by the formation of
intracellular bacterial colonies, which are less susceptible to standard antibiotic therapies [50,51].
Shielded from the host immune system, S. aureus colonies internalized by the cell provide a reservoir
of bacteria that is far more difficultly targeted by the oral or parenteral antibiotic administration routes
than bacteria colonizing the bone matrix [52]. To conceive of the right intracellular delivery carrier to
eliminate these internal colonies is thus an imperative in designing a perfectly potent anti-infective
drug delivery platform. The advantage of CAP nanoparticles is that they can also be utilized to deliver
antibiotics intracellularly and reduce the total bacterial population infesting the tissue. The alkaline
nature of the most frequently utilized CAP phase, HAP, also prevents the local drops in pH caused
by the bacterial colonies and thus minimizes the effect of reduced antibiotic effectivity in the acidic
milieu [53]. The effectiveness with which CAP nanoparticles can deliver antibiotics intracellularly
is demonstrated in Figure 4c, where a negative control population of osteoblastic, MC3T3-E1 cells
infected with fluorescent, FITC-tagged S. aureus is posed side by side with the same population of
cells treated with clindamycin-loaded CAP nanoparticles. Thanks to the efficient uptake of these
particles, the total bacterial number inside the cells drops and the average lifetime of the cells becomes
extended [54]. The antibacterial efficiency of antibiotics against an array of multidrug resistant bacteria
can thus be increased by a whole order of magnitude when delivered with CAP nanoparticles [55], the
reason presumably being the ability of the CAP carrier to penetrate the cell membrane and deliver its
load intracellularly.
4. CAP as a Foreign Ion Accommodator
One of the essential roles of CAP in the body, alongside serving as a major component of an organ
that provides a skeletal support for soft tissues and acts as a factory for the production of blood cells,
is to act as a mineral reservoir for the body [56]. In fact, the first evolutionarily formed CAP skeletons
presumably had the role of primitive tanks for storage and internal regulation of the concentration
of essential microelements. They also had a role to precipitate toxic ions that found their way into
the organism and enabled the latter to survive even in highly polluted environments [57]. Thanks to
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these superior ion-exchange properties, CAP, predominantly in the form of HAP, is being used as an
adsorbent in chromatographic columns [58,59] as well as in filters for the removal of toxic elements
from contaminated waters [60,61]. This propensity of CAP to engage in ionic substitutions is not
even closely matched by other abundant biominerals, such as calcium carbonates, calcium sulfate
or silica, let alone metallic particles synthesized by bacteria. It is possible owing to the enormous
charge balance flexibility of its crystal lattice and a broad range of Ca/P molar ratios for which the
space group of the lattice will be preserved. This makes CAP capable of accommodating more than
a half of all the elements of the Periodic Table [62]. In the case of HAP, for example, phosphate
groups can be readily substituted with groups such as carbonate (B-type HAP) [63], selenite [64],
vanadate [65], silicate [66], and others; calcium ions can be substituted with cations ranging in atomic
weight from as light as lithium [67] to as heavy as bismuth [68], thorium [69], and uranium [70]; also
hydroxyl groups can be substituted by ions as small as fluoride [71] and as large as carbonate (A-type
HAP) [72]. The ease with which these substitutions could be made through simple co-precipitation
reactions has led to a large body of research—albeit not very imaginative and somewhat trivial at
times—on ion-substituted CAPs and their effects on bioactivity, antimicrobial activity and other
biological properties of interest. To this day many ions have been incorporated into HAP in an
attempt to impart some of their unique properties to it. Particularly interesting in this context are HAP
incorporating magnetic ions (Fe2+/3+, Co2+/3+, Gd3+), photoluminescent ions (Eu3+, Yb3+, Tb3+, Y3+),
radioactive ions (125I´, 99mTc), reactive oxide species producing ions (Hf) and ions with pronounced
antibacterial (Ag+, Zn2+, Cu2+, Ga3+, SeO32´), osteoinductive (Mg2+, Sr2+, CO32´, SiO32´), angiogenic
(Mg2+, Si4+), antiresorptive (Zn2+) and, at times, anticancer properties (SiO32´, SeO32´). CAPs doped
with photoluminescent rare-earth elements provide for a low-cost, resorbable and safer alternative
as cell imaging probes to surface plasmonic nanoparticles and semiconductor quantum dots, while
retaining a number of advantages that the latter have over organic fluorophores, including higher
fluorescence intensity and photostability, broader absorption and narrower emission wavelength
ranges, less of the absorption/emission wavelength overlap, and others. For example, Eu3+-doped
HAP was capable of exhibiting multicolor luminescence under visible light excitation and resistance
to quenching up to 15 wt % of Eu3+ [73]. Additional substitutions of OH´ groups with F´ reduce
the vibrational modes of the lattice and prevent the quenching of the excited state of the rare-earth
ion, facilitating the fluorescent transition [74]. Unlike in the case of quantum dots, however, where
the color of the emitted light can be tuned by controlling the particle size, the emission bands can be
changed only by changing the chemical identity of the lanthanide dopant. Although the last ionic
additives incorporable into CAP will soon be off the list in terms of being integrated into CAP and
limitedly characterized for their properties, it will be a while before even the tip of the iceberg of
possibilities achievable through the synergy amongst different ionic dopants is revealed. Some of such
simultaneous incorporations of two or more types of ions into CAP, such as silver and lanthanides [75],
zinc and magnesium [76], selenite and manganese [77], europium and gadolinium [78], have already
been tested for their multifunctional properties.
Figure 5a displays the microstructure of magnetic, cobalt-doped HAP, having the average particle
size of 70 nm and exhibiting a more positive effect on regeneration of osteoporotic alveolar bone than
its nonmagnetic counterpart, in spite of imposing considerable cytotoxicity on bone cells (not epithelial
cells, too, interestingly) in vitro [79]. This and other magnetic CAPs are hoped to find an application
in anticancer hyperthermia therapies by replacing the more frequently used iron oxide nanoparticles
known for their long-term cytotoxicity [80]. Another application would be in magnetic-field-assisted
bone regeneration, a therapeutic process whose fundamentals have not been understood yet very well,
but whose benefits have been verified in numerous in vivo studies [81–83]. Figure 5b demonstrates the
antibacterial effect of selenite-doped HAP, increasing in direct proportion with the amount of selenite
incorporated into the structure of HAP. The choice of selenite is justified by the multifold effect it exerts
on biological systems: not only is it antibacterial in nature [84], but it can also exhibit pronounced
anticancer properties [85] as well as elicit an osteoinductive response from bone cells [86,87].
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Figure 5. (a) SEM image of hydroxyapatite nanoparticles in which Ca2+ ions were partially substituted
with Co2+ ions. The inlet shows an almost complete resorption of the implant and the regeneration of an
osteoporotic bone 24 weeks after the implantation (8—formation of Haversian canals; 11—ossification
frontline; 12—collagen fibers; all in-between is the region filled by the newly regenerated bone);
(b) TEM image of selenite-incorporating hydroxyapatite nanoparticles. The inlet shows the diameter of
E. coli growth inhibition zone around particles of selenite-doped hydroxyapatite as a function of the
concentration of selenite ions inside hydroxyapatite particles and depending on whether the selenite
ions were incorporated into the lattice by co-precipitation (´´) or by ion-exchange sorption (-‚-).
5. CAP as a aterial Formable into acroporous Constructs for Tissue Engineering
Pores of sufficient size, openness, and interconnectedness in an implant allow the cells to populate
its interior and proliferate therein. This pervasion of a biodegradable biomaterial with cells has
numerous benefits for the regeneration of a tissue temporarily replaced by its means [88]. Studies
on the effect of porosity on the proliferation and the osteoinductive response of cells have indeed
shown that macroporous CAP ceramics are favored over their dense, albeit mechanically stronger,
counterparts [89–91]. These insights have led to the demands for macroporous tissue engineering
constructs that are either seeded with cells prior to implantation in the form of scaffolds or acellular
and populated with the host cells after their placement in the body [92]. Although polymers
have been the traditional material of choice for making such constructs because of their superior
flow properties and moldability, CAP nanoparticles could also be formed into tissue engineering
constructs with precisely defined porosities using appropriate processing techniques. Freeze drying is
a technique that has been proven successful in synthesizing CAP scaffolds, albeit usually involving
co binations with a poly eric phase to i part a sufficient echanical integrity to the scaffold. This
technique is often co bined with sintering to i prove the toughness and the tensile strength of the
scaffolds [93]. Anisotropic lamination is observed under certain conditions, resulting in unusually high
compressive strengths as well [94], in analogy with the mechanical strengths typifying the anisotropic
microstructures of tooth enamel [95] and composite nacre [96]. Another frequently used method for
aking CAP scaffolds involves the seeding of CAP particles on the surface of a polymeric foam, whose
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subsequent burning leads to a porous ceramic construct [97]. Particle leaching methods involve the
dispersion of particulate additives inside CAP solids or pastes and their leaching upon bringing the
material in contact with a solution, leaving pores behind. Scaffolds created from calcium-deficient
self-setting HAP pastes via particle leaching, for example, had the interconnectivity of their micro- and
macro-pores controllable using the liquid-to-powder ratio [98]. Interestingly, simple setting reactions
in the absence of any porogens could also yield porous CAP solids permeable to cells, as exemplified
by the 50% porosity of hardened cements whose tunable release properties are shown in Figure 3b.
Thanks to their ability to form viscous pastes, CAP particles could be formed into
compact macroporous constructs using computer-aided additive manufacturing and various other
stereolithographic and robocasting processing methods. Both HAP [99] and biphasic HAP/TCP [100]
compositions were fabricated using 3D printing, the latter of which elicited a more positive
tissue integration response. These techniques allow for a far more precise design of the porosity
parameters—e.g., the distribution of pore sizes and shapes, the dimension and tortuosity of channels
connecting the pores, etc.—than the use of particle leaching or freeze drying as processing methods.
Consequently, they allow for a more accurate study of the effect of these porosity parameters on the
tissue response, the reason for which they are expected to fundamentally revolutionize the field of tissue
engineering in general in the near future and solve the enigma as to what the ideal microarchitecture
of CAP scaffolds is. Feedback looped with computerized axial tomography, 3D printed CAP scaffolds
can also be customized for individual patients and tailored to fit specific bone defects [101]. Such a
rapid prototyping setup is an ideal solution for implantable bone graft needs of patients in the clinic.
The question, however, remains as to whether the 3D printed (Figure 6a) or more imperfectly
formed CAP scaffolds (Figure 6b) will prove to possess a higher osseo-integrative and osteo-inductive
potential. The meaningfulness of this question is supported by multiple findings, including: (a) the
ability of irregularly shaped particles to be more therapeutically potent than their monodisperse and
perfectly spherical counterparts [102]; (b) the ability of surfaces containing disordered topographic
features to promote the differentiation of mesenchymal stem cells to osteoblasts without any
chemical factors, unlike their ordered and translationally symmetrical counterparts [103]; (c) the
more pronounced osteophilic nature of topographically irregular surfaces than that of their atomically
smooth counterparts [104–106]; (d) the realization that macroporous scaffolds with rough pore walls
induce a greater degree of new bone formation than the same scaffolds with smooth pore walls [107];
and (e) the fact that micropores are equally important in inducing the osteogenic response as the right
macroporosity [108]. In agreement with the basic premise of this discourse, which is that the restoration
of simplicity is the direction to follow in the design of new CAP biomaterials, it is foreseeable that
these sophisticated top-down fabrication methods will eventually give way to the simpler bottom-up
syntheses, the reason being the superior cell response and the corresponding cost-to-benefit ratio of
the latter. If CAP is an intrinsically imperfect material—cheap, rough, fragile, and lusterless, should
not its methods of synthesis adjust to its nature and be equally unpretentious and down-to-earth, that
is the question.
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(b) A HAP scaffold with less controllable pore size, shape and interconnectivity obtained by mixing 
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traditional view has held that to make CAP osteo-inductive in terms of being able to induce stem cell 
differentiation into mature bone cells and osteogenic in terms of being able to promote new bone 
growth, it would have to be supplemented with the appropriate growth factors, e.g., bone 
morphogenetic proteins and delivered in conjunction with cells, respectively [112]. However, the fact 
that CAP per se can augment the new bone formation and induce the osteogenic differentiation in the 
absence of any chemical factors is often overlooked. One example comes from Figure 7, where it is 
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pure HAP nanoparticles. However, after the cells have been treated with HAP loaded with 
clindamycin, the osteogenic response becomes “rescued”, demonstrating that the delivery of an 
osteoinhibitory drug such as the antibiotic clindamycin by means of HAP is able to compensate for 
the negative effects of the drug alone and either restore the osteogenic gene expression to the level of 
the control sample or in some cases significantly upregulate it with respect to these controls [113]. In 
another study the addition of HAP to a carboxymethyl cellulose hydrogel promoted the 
differentiation of dental pulp stem cells to osteoblastic lineage, as evidenced by the upregulated 
expression of Runx2, Col I, alkaline phosphatase, osteonectin, dentin matrix acidic phosphoprotein-1 
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leptin, leptin-R and Runx2 was also significantly higher in mesenchymal stem cells (MSCs) incubated 
with HAP or with a biphasic HAP/TCP mixture than in the control group [115]. Osteo-induction 
involving the upregulation of BSP and bone sialoprotein (BSP-2) was also detected in MSCs grown 
on biphasic CAP granules with different HAP/TCP weight ratios. Numerous other studies confirmed 
the ability of CAP to boost the osteoblastic differentiation, thereby deservedly endowing it with the 
attribute of osteo-inductive [116–119]. As far as the osteogenic response is concerned, studies 
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increased bone formation and enhanced bone repair and fusion around implants coated with CAP 
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obtained using 3D printing. Obtained from [109] with permission from ©2016 John Wiley & Sons;
(b) A HAP scaffold with less controllable pore size, shape and interconnectivity obtained by mixing
NaCl with a CAP paste, molding it under a pressure of 2 MPa, then immersing in water to leach out
NaCl, and finally vacuum drying to obtain the final, sponge-like scaffold. Obtained from [110] with
permission from ©2009 Elsevier.
6. CAP as a Naturally Osteo-Inductive and Osteogenic Material
CAP has been traditionally term d s an ost o o ductive material, as a ref r nce to its ability
to promote a viable contact with the boney tissues and become well integrated with them [111]. This
traditional view has held that to make CAP osteo-inductive in terms of being able to induce stem
cell differentiation into mature bone cells and osteogenic in ter s of being able to promote new
bone growth, it w uld have to be supplemente with the appropriate growth factors, e.g., bone
morphogenetic proteins and delivered in conjunction with cells, respectively [112]. However, the fact
that CAP per se can augment the new bone formation and induce the osteogenic differentiation in
the absence of any chemical factors is often overlooked. One example comes from Figure 7, where
it is seen, first of all, t at the administration of clindamycin to osteoblastic MC3T3-E1 cells, be they
uninfected with S. aureus (Figure 7a) or infected (Figure 7b), downregulates the expression of an
array of bone markers, i.e., osteocalcin (BGLAP), the transcription factor Runx2, type I procollagen
(Col I), and osteopontin (BSP-1). No such downregulation is observed when the sa e cells are treated
with pure HAP nanoparticles. However, after the cells h v be n treated with HAP loaded with
clindamycin, the osteogenic response becomes “rescued”, demonstrating that the delivery of an
osteoinhibitory drug such as the antibiotic clindamycin by means of HAP is able to compensate for
the negative effects of the drug alone and either restore the osteogenic gene expression to the level of
the control sample or in some cases sig ificantly u regulate it ith resp ct to these controls [113]. In
another study the addition of HAP to a carboxymethyl cellulose hydrogel promoted the differentiation
of dental pulp stem cells to osteoblastic lineage, as evidenced by the upregulated expression of
Runx2, Col I, alkaline phosphatase, osteonectin, entin matrix acidic phos hoprotein-1 and dentin
sialophosphoprotein after 21 days of culture [114]. The expression of oste g nic proteins leptin,
leptin-R and Runx2 was also significantly higher in mesenchymal stem cells (MSCs) incubated with
HAP or with a biphasic HAP/TCP mixture than in the control group [115]. Osteo-induction involving
the upregulation of BSP and bone sialoprotein (BSP-2) was also detected in MSCs grown on biphasic
CAP granules with different HAP/TCP weight ratios. Numerous other studies confirmed the ability
of CAP to boost the osteoblastic differentiation, thereby deservedly endowing it with the attribute
of osteo-inductive [116–119]. As far as the osteogenic response is concerned, studies evidencing
increased mineralization of cultured cells in the presence of CAP particles [120] and increased bone
formation and enhanced bone repair and fusion around implants coated with CAP [121,122] or
scaffolds supplemented with CAP [123] can serve as the evidence in its favor.
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Not all forms of CAP, however, are able to upregulate the expression of osteogenic markers
and boost new bone growth. Understanding the degree to which different particle properties—from
size to shape to agglomeration extent to surface charge to topography to microporosity to the exact
surface structure to hydration degree and the composition of the Stern layer and beyond—affect this
osteogenic response and how they act synergistically is an ongoing effort. For example, it is known
that nanosized CAP particles elicit a more intense osteogenic response in vitro than their micro-sized
counterparts [124,125]. Assessing all these individual properties at the nano scale is made difficult
due to the fact that small differences in the nanoparticle size are often more significant than the
transition from micro- to nano-sized particles itself. For instance, the melting point of some oxide
ceramics changes to a greater degree when the particle size is reduced from 20 to 10 nm than when
it is brought down from a few microns to 20 nm [126]. Likewise, nanoparticulate HAP was more
toxic to human bronchial epithelial cells when delivered at 50 µg/cm2 than when delivered at a twice
higher concentration [127]. With hundreds of studies on CAP being published every year, synthetic
efforts involving the compilation of data from different studies and deduction of the general findings
are today needed more than ever. Still, if CAP nanoparticle properties could be precisely optimized
for the most intense osteogenic response, there would be no need for the use of expensive growth
factors, as susceptible to degradation and prone to exert a plethora of side effects as they are [128–130],
which would have tremendous cost-effective repercussions on the development of osteogenic materials
in general.
7. CAP as a Natural Inhibitor of Osteoclastogenesis
Bisphosphonates are compounds used to mitigate bone loss due to osteoporosis. This therapeutic
outcome they achieve not by reinforcing new bone formation, but by slowing down the activity
of osteoclasts [131,132]. Although frequently overseen, CAPs can exhibit the very same effect
on osteoclasts. For example, as shown in Figure 8, the addition of RANKL as the promoter of
osteoclastogenesis in the RAW264.7 macrophage cell line elevates the mRNA transcript level of TRAP
as the osteoclastic gene expression marker. However, the mRNA transcript level of TRAP in cells
treated with both RANKL and CAP powders was at a similar level as that in the undifferentiated cells
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(Figure 8), indicating the inhibitory effect of CAP on the differentiation of RAW264.7 macrophages
into osteoclasts. In other words, CAP particles, regardless of their phase composition, are capable of
obliterating the effect of RANKL as a differentiation agent when added in combination to RAW264.7
cells. Similar findings were reported in a study by Stražic´-Geljic´ et al.: RAW264.7 cells subjected to
a simultaneous treatment with RANKL and CAP particles exhibited downregulation of genes such
as ACP5 and MMP9 [133]. Inhibition of proliferation, fusion, and TRAP activity of RAW264.7 cells
seeded on biphasic CAP ceramics was also reported [134] as well as inhibited differentiation of the
same cells into multinucleated osteoclasts upon seeding on a collagen scaffold containing HAP [135].
The complexity of the effects of nanostructured HAP exhibits on osteoclastogenesis is further evident
from a study in which HAP did cause a dose-dependent decrease in the osteoclastic gene expression
and resorption capacity of mature osteoclasts, but it also had the opposite, augmentative effect on these
very same parameters in undifferentiated peripheral blood mononuclear cells [136]. Moreover, as seen
from Figure 8, this inhibitory effect exhibited by CAP nanoparticles differs depending on the phase
composition of CAP and is most pronounced for HAP, the CAP phase naturally present in bone, and is
least pronounced for amorphous CAP. This is in agreement with the previously observed impairment
of the differentiation of primary mouse bone marrow macrophages into osteoclasts as a direct function
of the weight percentage of HAP in a HAP/TCP biphasic CAP [137]. The TRAP mRNA transcript
levels in cells treated with amorphous CAP or calcium pyrophosphate were insignificantly different
from that in undifferentiated cells. In contrast, the TRAP mRNA transcript levels in cells treated
with HAP or DCP anhydrous were significantly lower than that in undifferentiated cells (p < 0.05),
suggesting the possibility of tailoring the phase composition of CAP nanoparticles for the desired
osteoclastic activity following the surgical insertion of the particles into the body.
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8. CAP as a Natural Antimicrobial
The rapidly rising resistance of bacteria to antibiotics threatens to produce pandemics of tragic
proportions if the solution to this pending disaster is not reached timely [138]. At the moment, the
timeline for the passage of new antibiotics from the bench to the bedside is longer than that needed
for bacteria to evolve their resistance to it. One approach to solving this problem is based on seeking
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antimicrobial alternatives to organic molecules susceptible to the issue of bacterial resistance. Metallic
nanoparticles [139], bacteriophages [140], and antibacterial peptides [141] have been investigated in
search of these alternatives. All of these, however, are associated with considerable health risks for the
patient. Silver nanoparticles, for example, more researched for this application than any other inorganic
systems, are heavy metals and are, as such, hazardous by default. In fact, size-dependent cytotoxicity
of silver nanoparticles has been frequently observed in vitro [142–144]. As is the case with all viral
entities, the use of bacteriophages entails a finite immunological risk for the patient, even though they
are not human-specific [145]. They are also limited in terms of their ability to infect only a small number
of genetically different bacterial strains, which frequently renders them helpless against many chronic
infections, including osteomyelitis, wherein tissues become colonized by multiple genetic variants of
single or multiple bacterial species. Finally, antimicrobial peptides are costly to synthesize, store and
combine with the right carrier, alongside being broken down in the body relatively fast and carrying a
permanent risk of denaturing in the body and causing an inflammatory response. All in all, in spite of
their broad activity and low resistance potential, their potential immunogenicity, poor bioavailability
and high production costs have been stumbling blocks on the road to their transformation into a major
anti-infective drug type [146].
Another inherent weakness of traditional antibiotics comes from the nature of the mechanism of
their action: namely, their bactericidal and bacteriostatic effect is conditioned by the physical contact
of the drug with the cell membrane. In the case of osteomyelitis, however, a large percentage of
the bacterial population resides in the biofilm [147]. These cells are comparatively quiescent and
buried underneath a thick sheet of an exopolymeric substance that repels microbicides and makes the
cells largely inaccessible to antibiotics [148,149]. In addition, biofilms are powerful mediators of the
horizontal resistant gene transfer and of quorum sensing, the coordinated gene regulation response
by a bacterial population to an invader, making the cells inhabiting them also more intrinsically
resistant to antibiotics than the planktonic cells. An ideal antibacterial therapeutic is thus expected to
satisfy two essential prerequisites: (a) not to cause the target to develop resistance to the therapy; and
(b) not to harm the host. Neither the traditional antibiotics nor any of the aforementioned alternatives
satisfy these two essential prerequisites. Antimicrobial particles that could stay in the body for
prolonged periods of time without causing the inflammatory reaction or a cytotoxic response are
needed and CAP, a natural biomaterial, would be an excellent choice if it only had an antibacterial
activity. Interestingly, although CAPs usually do not possess any detectable antimicrobial properties,
they could be designed to possess them. For example, in a surface-active, nanoparticulate form, the
antibacterial activity of CAP can be comparable in strength to that of antibiotics such as vancomycin or
ciprofloxacin and is particularly pronounced against gram-negative bacteria, such as E. coli. This is
demonstrated in Figure 9a, where the number of bacterial colonies per volume of a broth following
overnight incubation with pure CAP pastes is comparable to or lower than that in broths incubated
with either CAP pastes loaded with antibiotics or antibiotics alone. Pure CAP is also extraordinarily
effective against P. aeruginosa biofilm, as demonstrated in Figure 9b. The mechanism for these unusual
antimicrobial effects is not clear yet, though it most probably stems either from surface chemistry
changes accompanying the amorphous-to-crystalline phase transitions involved in solidifying CAP
pastes or from the release of ultrafine CAP particles that block specific pathways or compartments in
bacteria and cause their death. Therefore, although CAP allows for the sustained release of antibiotics,
it can also substitute for their action and, thus, technically, eliminate the need for them. Finally, unlike
the aforementioned alternatives to traditional antibiotics, CAP is a nontoxic, bioresorbable material,
naturally present in the body, and is far less likely to cause any considerable health risks to the patients.
Our recent realization of the antibacterial properties possessed by the systematically optimized CAP
nanoparticles31 opens a new avenue in their research, extending far from the realm of bone regeneration
and into the broader area of anti-infective therapies and wound healing. If CAP as a bioactive coating
on load-bearing metallic implants in orthopedics could simultaneously endow the implant surface
with antifouling properties, it would present a major step forward in the design of advanced materials
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for bone regeneration. This step would proceed in the direction of which bone engineers could
have only dreamt: that is, how to create a surface that is bioactive, yet antifouling, a surface that is
welcoming for bone cells, yet repellant for bacteria? With CAP nanoparticles being increasingly used as
intravenous vehicles for the controlled, typically pH-responsive delivery of proteins [150–152], small
molecules [153–155], and calcium ions [156], entering the area of antimicrobials for prophylactic or
remedial purposes would be another step in the progression toward expanding the repertoire of their
applications in the biomedical arena.
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9. CAP as the Ugly Duckling Concealing a Swan Within
The sketching of the way for the future research in CAP performed here, undoubtedly promising,
can take on an almost fairytale character if we recall the plentiful of deficiencies that characterize
this material. For example, the hydrated and diffusive surface layer of ions prone to engage in
constant restructuring via dissolution/reprecipitation prevents the stable chemical conjugation of
CAP with therapeutic ligands and puts it, in that sense, behind materials such as silica, gold or
carbon nanotubes, let alone organic structures. Annealing could somewhat stabilize this surface
layer by increasing the crystallinity and lowering hydration; however, avoiding sintering, colloidal
destabilization, uncontrollable particle growth beyond the nanometer range, and reduced bioactivity
is an accompanying challenge.
Because of its characteristic growth proceeding through aggregation of Posner’s clusters and
larger particulate units, the control over particle size and morphology is challenging, to say the least.
As usual, however, the cause of a problem can be a key to its solution; in this case, this aggregational
growth endows CAP with a characteristically low crystal growth rate, involving the orientational
recognition of coalescing crystals through successive contact and dissolution [157], thus bearing more
resemblance to the growth of protein and viral crystals than of ordinary inorganic salts [158]. The
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effort to take advantage of this slow crystal growth to build attractive morphologies and architectures
on the nano scale using organic, biomimetic additives is, however, at its earliest beginnings in spite of
the decades of attempts to grow biominerals in the lab setting.
Then, although the solubility product is indeed a determinant of bioresorbability when it comes
to calcium orthophosphates [159], degradation of CAPs in vivo—like that of most ceramics except
the biosoluble ones—and the consequent release of the payload take place through cell/material
interaction (lactic acid release, phagocytosis, etc.) rather than through hydrolysis and/or physical,
porosity-controlled release as in the case of polymers. This implies that in spite of the ability of CAPs
to incorporate a plethora of therapeutically effective ionic species, their release is difficult to predict,
largely depending on the biological makeup of the area in the body in which CAP is being administered,
which is subject to large variations. Reflected in the highly complex and variable formation and phase
transition pathways, the compositional and structural volatility of CAPs is often considered as another
demerit of theirs, even though the potentials of its harnessing for various therapeutic or diagnostic
effects have been barely tapped into.
The low zeta potential of CAP particles, typically <˘15 mV in the entire pH range of stability [160],
is conducive to their aggregation, the reason for which their preparation in a lastingly stable colloidal
form needed for many gene and drug delivery applications is near to impossible without the use of
proper additives. This moderate instability of CAP dispersions can, however, be an advantage for
transfection, especially in 2D culture, where particle sedimentation is a prerequisite for cell/particle
contact to occur. Another propensity that should be in favor of CAPs as transfection agents is that
toward the attraction of an abundant and compositionally versatile protein corona, which, as it has
been shown [161], favors the uptake by the cells; though not measured in serum or cell culture media
yet, the lipoprotein corona around HAP particles passing through the pulmonary surfactant monolayer
was richer and, thus, more intrusive than that around hydrophobic polystyrene particles [162], being
the natural corollary of the excellent adsorption properties of CAP.
The fact that the atherosclerotic plaque is largely composed of HAP crystals [163,164], which
engage in epitaxial co-precipitation with cholesterol [165], presents another major concern before
the use of CAP nanoparticles as intravenously deliverable drug carriers. Fine tuning of the particle
structure and composition is, however, capable of overcoming this issue whose risks are minimal in
view of the fact that the serum is supersaturated with respect to CAP and that in a healthy organism the
intravenous delivery of CAP should not present an issue at low to moderate dosages. As a result, CAP
nanoparticles were safely delivered even at relatively high dosages of 300 mg/kg of body weight [166]
and were used for selective organ targeting even outside the reticuloendothelial system [167].
Though injectable, CAP pastes suffer from frequent filter-pressing problems caused by the
different flow rates of particles and the liquid medium under the extrusion pressure, resulting in
solid phase segregation and the clogging of the syringe [168]. On the other hand, they leave a large
room for the optimization of the flow and cohesion properties through the control over particle size
distribution, solid-to-liquid ratio, ionic strength, and viscosity of the liquid phase and other parameters,
thanks to which these issues could be overcome. The time sensitivity of their clinical application,
normally demanding in situ preparation just prior to the injection, presents another problem, mostly of
regulatory nature, tied to the use of injectable CAPs.
Last but certainly not least, problematic mechanical properties [169], including brittleness, low
fatigue resistance, low Weibull modulus, low fracture toughness, and low tensile and bending strengths
present another major limitation to the use of CAP in load-bearing implants in orthopedics and
dentistry. The tooth enamel, however, albeit not synthesizable in vitro as of today [170], has served
as a paradigmatic example of the ways in which the resistance to crack propagation, i.e., fracture
toughness, could be improved in the absence of any additives: through hierarchical ordering of CAP
particles with distinct symmetries at different spatial scales. In other words, many of the intrinsic
weaknesses of CAP have the potential to be overcome thanks to its structural, compositional, and
interactive versatility. After all, there may be a profounder analogy derivable from the fact that the
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choice for the main ingredient of the skeleton of our bodies fell in the course of evolution on none
other but this material than the usual reference to its sparsely soluble nature that endows CAP with
the optimal remodeling rate and allows it to act as a mineral reservoir in vivo. In short, it may suggest
that the foundations for the design of versatilely applicable nanostructures in biomedicine should
similarly be built out of CAPs.
10. Conclusions
Designing therapeutic nanoparticles for use in tissue engineering and drug delivery, while taking
regional social practices and limitations into account, is a rare concept among biomedical scientists.
It is, however, a concept that reconnects with E. F. Schumacher’s ideal also known as “small is
beautiful” [171], according to which the transfer of technologies from rich to poor populations must be
accompanied by the modification of these very same technologies in terms of their size, scale and other
characteristics, all for the purpose of their matching the limitations within which the local communities
thrive. Nanotechnologies are by no means an exception to this necessity to understand the context
of the local culture to which the new technology is exported and adjusting it accordingly in order to
ensure its congruous adoption and contribution to sustainable development [172]. With the science
of nanoparticle synthesis, characterization, and functionalization often being termed “science of the
small”, these two emphases on “small”, one of which is scientific in nature and the other one of which
is societal, should perhaps be pursued in parallel more often than they are.
In this review we have shown that designing a nanoparticle for such a socially responsible tissue
engineering application requires going against the stream defined by the current trends in the evolution
of scientific thought in the field of nanoscience and nanotechnologies. In particular, while there is no
doubt that the future in the realm of nanoparticle synthesis belongs to the further complexification
of its structure and properties, this review serves the purpose of demonstrating that sometimes it
may pay off to move in the opposite direction, that is, against the mainstream and against the trends
imposed by the scientific community. In other words, to simplify the nanoparticle structure might
lead to tremendous social benefits. Specifically, we have shown that CAP is a multifaceted material
that conceals an array of utilizable latent properties. Revealing them is especially fulfilling given
the history of deficiencies that epitomize CAPs and that limit their use as biomaterials, including
brittleness, low fracture toughness, incapacity for stable chemical conjugation, a formidable processing
potential compared to metals, non-oxide ceramics or polymers, etc. Though CAP has been traditionally
considered a “poor man’s material” among tissue engineers, an extraordinary richness of properties
hidden underneath this ostensible poverty is being increasingly revealed, the continued elicitation
of which and consideration for use in biomedicine irresistibly echoes Mother Teresa’s celebration of
poverty in every aspect of living.
In this review we call for the partial reversal of the direction of research in CAP, from
complexification to simplification, finding in the versatility of properties dormant in this material
the route for its promotion into a key material for socially responsible tissue engineering. Further
investigation of this intrinsic proteanism may bring us closer to an affordable-to-all bone replacement
material containing multifunctional CAP as a sole component. Although we foresaw in this study
CAP as a potential compensator for the role of antibiotics, osteogenic growth factors, antiresorptive
bisphosphonates, radiographic and contrast agent molecules, optically active compounds, polymers
as viscous components, polymers as additives enabling controlled drug release, and multiple other
exquisite components of tissue engineering constructs, we do not wish to trivialize or discourage future
research on supplementation of CAP with all these different components. Rather, what we call for is a
complementation of this indisputably valuable line of research whose aim is further complexification
of the biomaterial structure with a reverse path, whose aim is continued exposition of medically
applicable properties dormant in CAP alone. Such a fundamental line of research may simultaneously
bring us closer to a practical, therapeutic option that would be utterly inexpensive, in situ synthesizable
and affordable to practically every region of the world, from the wealthiest to the poorest. To that end,
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one such research would not only be guided with the socially aware eye focused on the whole, but
would also contribute to the healing of the gap between rich and poor, the gap whose impassability
presents one of the most critical threats for the sustainability of the Earth as we know it.
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